Ignite Creation Date:
2024-05-06 @ 8:07 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06261138
Status:
COMPLETED
Last Update Posted:
2024-02-15
First Post:
2024-02-07
Brief Title:
Survival Analysis TACE vs Combination Therapy in HCC
Sponsor:
Zhejiang University
Organization:
Zhejiang University
Study Overview
Official Title:
Survival Analysis of TACE Monotherapy vs Combination Therapy in BCLC B and C Stage Hepatocellular Carcinoma A Retrospective Cohort Study
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This retrospective observational study aimed to assess potential improvements associated with systemic therapies in patients receiving transarterial chemoembolization TACE for initially unresectable HCC
Detailed Description:
Standard treatments provide limited benefits for patients with intermediate or advanced hepatocellular carcinoma HCC Recently recommendations on multimodal treatment regimens for patients with locally advanced HCC have attracted much attention Therefore this retrospective research was designed to evaluate the clinical outcomes of TACE alone or in combination with immune and targeted therapy in the primary treatment for patients with intermediate to advanced stage HCC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None